Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP3 | P15309 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
| ▸ | PRKCA | P17252 | 1/20 | 0.43 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | MLYCD | O95822 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11393286 | 0.87 | ACP3 (0.49) | ACP3MEN1KMT2AMAPTMAOB | |
| SCHEMBL17457779 | 0.83 | ACP3 (0.65) | ACP3MEN1KMT2AMAPTHTT | |
| SCHEMBL4990438 | 0.82 | VNN1 (0.42) | MEN1KMT2AMAOBIDO1NR4A2 | |
| SCHEMBL4993311 | 0.82 | VNN1 (0.49) | — | |
| SCHEMBL6865758 | 0.81 | MEN1 (0.62) | ACP3MEN1KMT2AMAPTHTT | |
| SCHEMBL4994252 | 0.81 | ACP3 (0.51) | ACP3MEN1KMT2AMAPTHTT | |
| SCHEMBL6264197 | 0.80 | CTBP2 (0.47) | ACP3KMT2AALDH1A1POLBMAOB | |
| SCHEMBL30632615 | 0.80 | HTT (0.60) | ACP3MEN1KMT2AMAPTHTT | |
| SCHEMBL4338 | 0.80 | HTT (0.60) | ACP3MEN1KMT2AMAPTHTT | |
| SCHEMBL187207 | 0.79 | KDM4E (0.59) | MEN1KMT2AMAPTHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7414071-B2 | Methods of treatment with selective EP4 receptor agonists | PFIZER INC. (US) | 2008-08-19 | — | — | US | disclosed |
| EP-1339678-B1 | EP4 RECEPTOR SELECTIVE AGONISTS IN THE TREATMENT OF OSTEOPOROSIS | PFIZER PROD INC (US) | 2007-09-26 | — | — | EP | disclosed |
| US-20070191319-A1 | Treatment of conditions that present with low bone mass by continuous combination therapy with selective prostaglandin ep4 receptor agonists and an estrogen | PFIZER INC. (US) | 2007-08-16 | — | — | US | disclosed |
| US-7192979-B2 | EP4 receptor selective agonist in the treatment of osteoporosis | PFIZER INC. (US) | 2007-03-20 | — | — | US | disclosed |
| EP-1696893-A1 | CONTINUOUS COMBINATION THERAPY WITH SELECTIVE PROSTAGLANDIN EP4, RECEPTOR AGONISTS AND AN ESTROGEN FOR THE TREATMENT OF CONDITIONS THAT PRESENT WITH LOW BONE MASS. | Pfizer Products Incorporated (US) | 2006-09-06 | — | — | EP | disclosed |
| EP-1487437-B1 | USE OF SELECTIVE EP4 RECEPTOR AGONISTS FOR THE TREATMENT OF DISEASES | PFIZER PROD INC (US) | 2006-08-16 | — | — | EP | disclosed |
| EP-0930296-B2 | FLUORINATED PROSTAGLANDIN DERIVATIVES AND MEDICINES | ASAHI GLASS CO LTD (JP) | 2005-11-02 | — | — | EP | disclosed |
| WO-2005060946-A1 | CONTINUOUS COMBINATION THERAPY WITH SELECTIVE PROSTAGLANDIN EP4, RECEPTOR AGONISTS AND AN ESTROGEN FOR THE TREATMENT OF CONDITIONS THAT PRESENT WITH LOW BONE MASS | PFIZER PRODUCTS INC. (US) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005027931-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS COMPRISING COMBINATIONS OF 2-ALKYLIDENE-19-NOR-VITAMIN D DERIVATIVES AND AN EP2 OR EP4 SELECTIVE AGONIST | PFIZER PRODUCTS INC. (US) | 2005-03-31 | — | — | WO | disclosed |
| US-20050065133-A1 | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and an EP2 or EP4 selective agonist | PFIZER INC | 2005-03-24 | — | — | US | disclosed |
| WO-2003047513-A2 | METHOD FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2003-06-12 | — | — | WO | disclosed |
| US-6552067-B2 | For therapy of osteoporosis, frailty, an osteoporotic fracture, a bone defect, childhood idiopathic bone loss, alveolar bone loss, mandibular bone loss, bone fracture, osteotomy, bone loss associated with periodontitis | PFIZER INC. | 2003-04-22 | — | — | US | disclosed |
| EP-0930296-B1 | FLUORINATED PROSTAGLANDIN DERIVATIVES AND MEDICINES | ASAHI GLASS CO LTD (JP) | 2002-07-24 | — | — | EP | disclosed |
| US-20020065308-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | LOTUS PHARMACEUTICAL CO., LTD. (JP) | 2002-05-30 | — | — | US | disclosed |
| WO-2002042268-A2 | EP4 RECEPTOR SELECTIVE AGONISTS IN THE TREATMENT OF OSTEOPOROSIS | PFIZER PRODUCTS INC. (US) | 2002-05-30 | — | — | WO | disclosed |
| US-20020040149-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | CAMERON KIMBERLY O'KEEFE (US) | 2002-04-04 | — | — | US | disclosed |
| US-20010047105-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PFIZER PRODUCTS INC. | 2001-11-29 | — | — | US | disclosed |
| WO-2001046140-A1 | EP4 RECEPTOR SELECTIVE AGONISTS IN THE TREATMENT OF OSTEOPOROSIS | PFIZER PRODUCTS INC. (US) | 2001-06-28 | — | — | WO | disclosed |
| EP-1110949-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | Pfizer Products Inc. (US) | 2001-06-27 | — | — | EP | disclosed |
| EP-0930296-A1 | FLUORINATED PROSTAGLANDIN DERIVATIVES AND MEDICINES | ASAHI GLASS COMPANY LTD. (JP) | 1999-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191319-A1 | Treatment of conditions that present with low bone mass by continuous combination therapy with selective prostaglandin ep4 receptor agonists and an estrogen | PTGER4, PTGER1, PTGFR | ACP3 300/4885MEN1 3451/4885KMT2A 2838/4885 |
| US-20050065133-A1 | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and an EP2 or EP4 selective agonist | VDR, CYP24A1, CYP2R1 | ACP3 770/4885MEN1 1543/4885KMT2A 2635/4885 |
| US-20020040149-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PTGER4, PTGER1, PTGER2 | ACP3 1392/4885MEN1 4541/4885KMT2A 2801/4885 |
| US-20020065308-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PTGER4, PTGER1, PTGER2 | ACP3 1105/4885MEN1 4447/4885KMT2A 2280/4885 |
| US-20010047105-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PTGER4, PTGER1, PTGER2 | ACP3 1392/4885MEN1 4541/4885KMT2A 2801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.